Art. 4 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2019cited 61×
1.

Applications for the marketing authorisations referred to in Article 3 shall be submitted to the Agency.

2.

The Union shall grant and supervise marketing authorisations for medicinal products for human use in accordance with Title II.

3.

The Union shall grant and supervise marketing authorisations for veterinary medicinal products in accordance with Title III.

The 10 that are cited most themselves, of 61.

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    On 28 February 2012, Biogen Idec submitted to the EMA an application for marketing authorisation for Tecfidera – Dimethyl fumarate (‘Tecfidera – Dimethyl fumarate’ or ‘Tecfidera’), a medicinal product for human use, in …

    5 May 2021 · 62018TJ0611

  • Judgment of the Court (Fourth Chamber) of 16 March 2023. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    Article 4(1) of that regulation provides: ‘Applications for the marketing authorisations referred to in Article 3 shall be submitted to the [EMA].’

    16 Mar 2023 · 62021CJ0438

  • Order of the President of the General Court of 4 August 2022. Biogen Netherlands BV v European Commission.Decision

    On 28 February 2012, Biogen Idec Limited lodged with the European Medicines Agency (EMA) an application for marketing authorisation, pursuant to Article 4(1) of Regulation (EC) No 726/2004 of the European Parliament and of the Council of …

    4 Aug 2022 · 62022TO0278

  • Order of the President of the General Court of 4 August 2022. Biogen Netherlands BV v European Commission.Decision

    On 28 February 2012, Biogen Idec Limited lodged with the European Medicines Agency (EMA) an application for marketing authorisation, pursuant to Article 4(1) of Regulation (EC) No 726/2004 of the European Parliament and of the Council of …

    4 Aug 2022 · 62022TO0269

  • Order of the President of the General Court of 4 August 2022. Biogen Netherlands BV v European Commission.Decision

    On 28 February 2012, Biogen Idec Limited lodged with the European Medicines Agency (EMA) an application for marketing authorisation, pursuant to Article 4(1) of Regulation (EC) No 726/2004 of the European Parliament and of the Council of …

    4 Aug 2022 · 62022TO0279

  • Order of the Court (Eighth Chamber) of 14 May 2012. Sepracor Pharmaceuticals (Ireland) Ltd v European Commission.Decision

    14 May 2012 · 62011CO0477

  • Judgment of the General Court (Sixth Chamber) of 19 December 2019. Vanda Pharmaceuticals Ltd v European Commission.Decision

    On 4 December 2015 the applicant, pursuant to Article 4 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal …

    19 Dec 2019 · 62018TJ0211

  • Regulation (EU) 2019/5Lawamends

  • Judgment of the General Court (Second Chamber) of 15 September 2015. Novartis Europharm Ltd v European Commission.Decision

    … киселина“ (наричан по-нататък „Zoledronic acid Teva Pharma“) на основание член 4, параграф 1 от Регламент № 726/2004.

    15 Sep 2015 · 62012TJ0472

  • Order of the President of the General Court of 29 February 2024. Neuraxpharm Pharmaceuticals SL v European Commission.Decision

    On 28 February 2012, Biogen Idec Ltd filed an application with the European Medicines Agency (EMA), pursuant to Article 4(1) of Regulation No 726/2004, for a marketing authorisation (‘MA’) for the medicinal product ‘Tecfidera – …

    29 Feb 2024 · 62023TO1182